Tag Archives: ACA
By Guest Blogger | Published: October 9, 2013
by Tom Norton While US Pharma anxiously watches the initial roll out of Obamacare, there are those entities closely associated with the innovator Rx business that have a very different view on what Obamacare means to their concerns. These firms are carefully circling the new law, thoughtfully observing its implementation, and, generally, viewing its startup […]
By Jill Wechsler | Published: July 22, 2013
What was once an obscure federal policy for providing low-cost drugs to safety-net hospitals has grown into a program that requires extensive discounting to one-third of the nation’s hospitals and health clinics. Pharma companies are pushing back, heightening tensions between “covered entities” that qualify for greatly reduced prices on medicines under 340B — and manufacturers […]
By Guest Blogger | Published: May 21, 2013
by Tom Norton If you are an Rx regional sales director or a product marketing manager, I have a somewhat provocative question for you: How exactly are you planning your 2014 Medicaid strategy?
By Guest Blogger | Published: May 16, 2013
By Les Funtleyder. The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof. With respect to investing, uncertainly caused by media/pundit noise often depresses valuations […]
By Guest Blogger | Published: April 4, 2013
by William Kitchens On March 21, 2013, the United States Senate approved an amendment by a vote of 79 to 20 to repeal the 2.3 percent medical device excise tax. The tax, which went into effect this past January, was included as part of the Patient Protection and Affordable Care Act.